Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jan;57(1):102-3.
doi: 10.1007/s00108-015-3848-z.

[New Therapy Option for Type 2 Diabetes Mellitus: EMPA-REG Study]

[Article in German]
Affiliations
Comment

[New Therapy Option for Type 2 Diabetes Mellitus: EMPA-REG Study]

[Article in German]
E Windler et al. Internist (Berl). .

Comment on

  • Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Zinman B, et al. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. N Engl J Med. 2015. PMID: 26378978 Clinical Trial.

Similar articles

See all similar articles

MeSH terms

Substances

LinkOut - more resources

Feedback